A randomized, open-label study of the effect of Bondronat [ibandronic acid] compared with zoledronic acid on bone turnover, bone resorption, and bone formation in patients with metastatic bone disease from breast cancer.

Trial Profile

A randomized, open-label study of the effect of Bondronat [ibandronic acid] compared with zoledronic acid on bone turnover, bone resorption, and bone formation in patients with metastatic bone disease from breast cancer.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Ibandronic acid; Zoledronic acid
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 16 Feb 2008 Status changed from in progress to completed.
    • 20 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top